Research is uncovering ways in which sex as a biological variable affects health. The social environment’s effect on our biology also is increasingly acknowledged, along with data indicating that these effects vary by gender. Thus, both biological sex and gendered experience can play a role in the physiological mechanisms of disease. A newly published paper in the journal Cell asserts that despite the challenges in navigating the paradigm shift required to study the effects of sex and gender as well as the biological and social determinants of health, the future of science is to study how these factors intersect.
News
Information about the Supreme Court Decision Dobbs vs Jackson’s Women’s Health Organization
These are articles written and shared by our Yale Law professors Linda Greenhouse, Reva Siegel and Priscilla Smith:
Requiem for the Supreme Court, New York Times Opinion by Linda Greenhouse
The Trump court limited women’s rights using 19th-century standards, The Washington Post Perspective by Riva Siegel
What if Roe fell?, Center for Reproductive Rights
Latest News
Women’s Health Research at Yale today announced two research awards, one aimed at more effectively treating endometriosis and the second designed to help women who have been incarcerated improve their health outcomes.
- July 03, 2024
Yale School of Medicine and its clinical provider, Yale Medicine, take center stage in a display in Times Square
- July 01, 2024
A look at the 2024 Yale Obstetrics, Gynecology and Reproductive Sciences Research and Graduation Day through photos.
- June 19, 2024Source: OncLive
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center, discusses findings from a subanalysis of the phase 3 NETTER-2 study (NCT03972488) investigating frontline lutetium Lu 177 dotatate (Lutathera) in patients with advanced, well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
- June 19, 2024Source: OncLive
Barbara Burtness, MD, professor of medicine, Medical Oncology, chief translational research officer, chief, Head and Neck Cancers/Sarcoma, co-leader, Developmental Therapeutics, associate cancer center director for translational research, Yale Cancer Center, discusses subgroup outcomes from the phase 2 E3311 trial (NCT01898494) evaluating primary transoral surgery and postoperative radiation deintensification strategies for patients with human papillomavirus (HPV)–associated oropharynx cancer.
- June 12, 2024Source: Yale New Haven Health
Yale New Haven Health (YNHHS) celebrated the second YNHHS Innovation Awards Ceremony, where five outstanding teams were each awarded $100,000 to bring their groundbreaking projects to life.
- June 11, 2024
Faculty from across the Yale Department of Internal Medicine are using artificial intelligence (AI) as a tool to help improve the way they learn, teach, conduct research, and advance the field of medicine.
- June 07, 2024
Yale Cancer Center scientists and trainees attended the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago May 31-June 4 to present research advances from Yale Cancer Center and Smilow Cancer Hospital. The ASCO meeting is the most significant gathering of oncology professionals worldwide, initiating connections and forging collaborations that can change the landscape of cancer care.
- June 05, 2024Source: eCancer
Dr Barbara Burtness, chief of head and neck cancers/sarcoma at Yale Cancer Center, speaks to ecancer at ASCO 2024 about the long-term follow up results of E3311, a phase II trial of transoral surgery followed by pathology-based adjuvant treatment in HPV-associated oropharynx cancer.
- June 01, 2024
Yale Cancer Center and Smilow Cancer Hospital people who have been honored